Search
Abstract
The receptor for advanced glycation end-products (RAGE or AGER) is a transmembrane, immunoglobulin-like receptor that, due to its multiple isoform structures, binds to a diverse range of endo- and exogenous ligands. RAGE activation caused by the ligand binding initiates a cascade of complex pathways associated with producing free radicals, such as reactive nitric oxide and oxygen species, cell proliferation, and immunoinflammatory processes. The involvement of RAGE in the pathogenesis of disorders such as diabetes, inflammation, tumor progression, and endothelial dysfunction is dictated by the accumulation of advanced glycation end-products (AGEs) at pathologic states leading to sustained RAGE upregulation. The involvement of RAGE and its ligands in numerous pathologies and diseases makes RAGE an interesting target for therapy focused on the modulation of both RAGE expression or acti-vation and the production or exogenous administration of AGEs. Despite the known role that the RAGE/AGE axis plays in multiple disease states, there remains an urgent need to develop noninvasive, molecular imaging approaches that can accurately quantify RAGE levels in vivo that will aid in the validation of RAGE and its ligands as biomarkers and therapeutic targets. This article is categorized under: Diagnostic Tools > In Vivo Nanodiagnostics and Imaging Diagnostic Tools > Biosensing
Citations
-
3
CrossRef
-
0
Web of Science
-
4
Scopus
Authors (8)
-
Iwona T. Dobrucki
-
Angelo Miskalis
-
Michael B. Nelappana
-
Catherine C. Applegate
-
Marcin Woźniak
-
Andrzej Czerwinski
-
Lawrence W. Dobrucki
Cite as
Full text
- Publication version
- Accepted or Published Version
- DOI:
- Digital Object Identifier (open in new tab) 10.1002/wnan.1935
- License
-
open in new tab
Keywords
Details
- Category:
- Articles
- Type:
- artykuły w czasopismach
- Published in:
-
Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology
no. 16,
ISSN: 1939-5116 - Language:
- English
- Publication year:
- 2024
- Bibliographic description:
- Dobrucki I. T., Miskalis A., Nelappana M. B., Applegate C. C., Woźniak M., Czerwinski A., Kalinowski L., Dobrucki L. W.: Receptor for advanced glycation end‐products: Biological significance and imaging applications// Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology -Vol. 16,iss. 1 (2024),
- DOI:
- Digital Object Identifier (open in new tab) 10.1002/wnan.1935
- Sources of funding:
-
- Funded in part by the Pilot Grant from Cancer Center at Illinois (Lawrence W. Dobrucki), Polish Ministry of Education and Science, grants no. 10/E-389/SPUB/SP/2020 (Leszek Kalinowski) and DIR/WK/2017/01 (Leszek Kalinowski, Lawrence W. Dobrucki)
- Verified by:
- Gdańsk University of Technology
seen 56 times
Recommended for you
Molecularly targeted nanoparticles: an emerging tool for evaluation of expression of the receptor for advanced glycation end products in a murine model of peripheral artery disease
- M. Woźniak,
- C. J. Konopka,
- A. Płoska
- + 7 authors
Quantitative Analysis of Biofilm Formed on Vascular Prostheses by Staphylococcus Epidermidis with Different ica and aap Genetic Status
- J. Golus,
- M. Stankevic,
- R. Sawicki
- + 3 authors
Synthesis, Chemical Characterization and Multiscale Biological Evaluation of a dimericcRGD Peptide for Targeted Imaging of αVβ3 Integrin Activity
- J. Hedhli,
- A. Czerwiński,
- M. Schuelke
- + 11 authors